ADIPOQ and colorectal carcinoma: Adiponectin as an insulin-sensitizing agent and a negative regulator of angiogenesis is secreted mainly from visceral adipose tissue, which could inhibit CRC growth in animal models, and its circulating concentrations were associated with CRC risk in clinical trials [42].